Enzo Biochem Q2 EPS $(0.06) Up From $(0.23) YoY, Sales $8.55M
Save time and jump to the most important pieces.
SC 13G/A - ENZO BIOCHEM INC (0000316253) (Subject)
SC 13G/A - ENZO BIOCHEM INC (0000316253) (Subject)
SC 13G - ENZO BIOCHEM INC (0000316253) (Subject)
8-K - ENZO BIOCHEM INC (0000316253) (Filer)
10-K - ENZO BIOCHEM INC (0000316253) (Filer)
8-K - ENZO BIOCHEM INC (0000316253) (Filer)
4 - ENZO BIOCHEM INC (0000316253) (Issuer)
4 - ENZO BIOCHEM INC (0000316253) (Issuer)
4 - ENZO BIOCHEM INC (0000316253) (Issuer)
FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights The Company's revenues in the 2024 period of $31.9 million improved year-over-year by 3%. Enzo's sales to its industrial customers, which includes biotech and pharmaceutical companies, increased 46% driven by our drug development and cell and gene therapy focus.The Company's FY24 gross margin was 46%. The prio
FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal third quarter ended April 30, 2024. Third Quarter Highlights The Company's Life Science division's third-quarter revenue of $8.0 million improved year-over-year by 7%, marking four consecutive quarters of revenue growth compared to the prior year quarterly periods. Revenue for the nine months ended April 30, 2024 of $24.4 million improved 10% compared to the same year-to-date period in the prior year. Focus on the Company's drug development tools segment is a key driver of the year-to-date growth.The Life Science division's third-qu
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights The Company's Life Science division's second-quarter revenue of $8.5 million improved year-over-year by 14%. During the 2024 period, we experienced a 25% revenue increase in the United States, driven by increased product demand in the drug development and cell and gene therapy market segments. Revenue for the six months ended January 31, 2024 of $16.4 million improved 12% compared to the same period in the prior year.The Life Science division's second-quarter gross m
FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights The Company's revenues in the 2024 period of $31.9 million improved year-over-year by 3%. Enzo's sales to its industrial customers, which includes biotech and pharmaceutical companies, increased 46% driven by our drug development and cell and gene therapy focus.The Company's FY24 gross margin was 46%. The prio
Highlights the Destruction of 70% in Stockholder Value Under Garry Mauro's 10-Year Reign as Chairman Notes the Radoff-Sudbury Group's Aligned and Highly Qualified Director Candidates Collectively Own Significantly More Stock than the Entire LifeVantage Board and are Committed to Acting in Stockholders' Best Interests Urges Stockholders to Vote for the Radoff-Sudbury Group's Director Candidates – Dayton Judd, Michael Lohner and Bradley L. Radoff – on the BLUE Proxy Card Ahead of LifeVantage's Upcoming Annual Meeting Bradley L. Radoff and Sudbury Capital Fund, LP (together with their affiliates, the "Radoff-Sudbury Group" or "we"), who collectively own approximately 12.8% of the outstan
FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo Biochem" or the "Company"), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the "Special Meeting") to consider and vote on a proposal to approve the sale (the "Asset Sale") of substantially all the assets and assignment of certain liabilities of its clinical laboratory business to Laboratory Corporation of America Holdings, a Delaware corporation ("Labcorp") and adopt the Asset Purchase Agreement, dated as of March 16, 2023 (as such agreement may be amended from time to time, the "Asset Purchase Agreement"), by and among the Company, Enzo Clinic
Shares of PriceSmart, Inc. (NASDAQ:PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings of $1.31 per share, beating market estimates of $1.25 per share. PriceSmart’s quarterly sales came in at $1.29 billion versus expectations of $1.28 billion, according to data from Benzinga Pro. PriceSmart shares surged 4.6% to $86.90 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Marin Software Incorporated (NASDAQ:MRIN) shares rose 76.1% to $0.5054 in pre-market trading after the company announced upgrades to its Microsoft Corp (NASDAQ:MSFT) adver
FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual Shareholder Meeting Proposals Proposal One – The shareholders elected Kara Cannon, Steven J. Pully, Bradley L. Radoff, and Mary Tagliaferri, M.D. to the Company's Board of Directors to hold office for a term ending as of our Fiscal 2024 annual meeting of shareholders, and until each such director's successor is elected and qualified. Proposal Two – The shareholders did not approve, by a non
FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo's Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. "We thank Hamid for the commitment he has brought to Enzo Biochem, Inc." Chairperson of the Board Mary Tagliaferri, MD stated, "Hamid successfully led the Company through the divestiture of Enzo Clinical Lab, Inc. We wish him well in all his future endeavors and are excited to focus on the life sciences division. We are confident in Kara to lead th
NEW YORK, NY, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, today announced the appointment of Patricia Eckert, CPA, as interim Chief Financial Officer (CFO). Ms. Eckert's appointment follows the resignation of David Bench, who is departing the Company effective November 14, 2022 to pursue a new opportunity. "While bittersweet in light of David's departure, we are exceedingly pleased to have Patricia in position to advance into the position of interim CFO," remarked Hamid Erfanian, CEO of Enzo. "Patricia is exceptionally qualified given her years of experience and comprehensive knowledge of Enzo'